Linked Life Data

20080226

Source:http://linkedlifedata.com/resource/pubmed/id/20080226

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2010-5-31
pubmed:abstractText
The purpose of this study was to explore the potential of toll-like receptor-3 stimulation, with polyI:C(12)U (poly[l].poly[C(12),U]; rintatolimod [Ampligen; Hemispherx Biopharma, Philadelphia, PA]) to enhance bioactivity of cancer immunotherapies.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1097-6868
pubmed:author
pubmed:copyrightInfo
Copyright 2010 Mosby, Inc. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
202
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
608.e1-8
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapy.
pubmed:affiliation
Advanced Immune Therapeutics, Inc., Medford, MA, USA.
pubmed:publicationType
Journal Article, Research Support, N.I.H., Extramural